Octreotide for arrest of peptic ulcer hemorrhage - A prospective, randomized controlled trial

H. J. Lin, C. L. Perng, K. Wang, C. H. Lee, S. D. Lee

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background/Aims: A prospective, randomized controlled trial was performed over a 10-month period to evaluate the hemostatic effects of octreotide and ranitidine in 84 patients with active peptic ulcer bleeding or nonbleeding visible vessels at the ulcer bases. Patients and Methods: Forty-two patients received octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 ± 0.6 days (mean ± SD). The other 42 patients received ranitidine 100 mg intravenously every 12 h. The two groups were matched for sex, age, location of bleeders, endoscopic findings, shock, and initial hemoglobin. Results: Hemostasis was obtained in 35 (83.3%) of the octreotide group, and 23 (54.8%) of the control group (p <0.01). Volume of blood transfused, numbers of patients receiving aggressive management (endoscopic hemostasis or operation), and hospital stay were significantly less in the octreotide group as compared with those of the controls (p <0.05, p <0.05 and p <0.001, respectively). No obvious side effect was found in the octreotide group. Conclusion: We suggest that octreotide is a safe and effective drug in arresting peptic ulcer hemorrhage. It may be used as the first-line therapy for a patient with massive peptic ulcer hemorrhage before he is transferred to a medical center.

Original languageEnglish
Pages (from-to)856-860
Number of pages5
JournalHepato-Gastroenterology
Volume42
Issue number6
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Peptic Ulcer Hemorrhage
Octreotide
Randomized Controlled Trials
Ranitidine
Endoscopic Hemostasis
Hemostatics
Blood Volume
Hemostasis
Peptic Ulcer
Ulcer
Shock
Length of Stay
Hemoglobins
Research Design
Hemorrhage
Control Groups

Keywords

  • Hemostasis
  • Operation
  • Rebleeding
  • Shock

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Octreotide for arrest of peptic ulcer hemorrhage - A prospective, randomized controlled trial. / Lin, H. J.; Perng, C. L.; Wang, K.; Lee, C. H.; Lee, S. D.

In: Hepato-Gastroenterology, Vol. 42, No. 6, 1995, p. 856-860.

Research output: Contribution to journalArticle

Lin, H. J. ; Perng, C. L. ; Wang, K. ; Lee, C. H. ; Lee, S. D. / Octreotide for arrest of peptic ulcer hemorrhage - A prospective, randomized controlled trial. In: Hepato-Gastroenterology. 1995 ; Vol. 42, No. 6. pp. 856-860.
@article{0ff117c4adf7487da645f42bf184aaef,
title = "Octreotide for arrest of peptic ulcer hemorrhage - A prospective, randomized controlled trial",
abstract = "Background/Aims: A prospective, randomized controlled trial was performed over a 10-month period to evaluate the hemostatic effects of octreotide and ranitidine in 84 patients with active peptic ulcer bleeding or nonbleeding visible vessels at the ulcer bases. Patients and Methods: Forty-two patients received octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 ± 0.6 days (mean ± SD). The other 42 patients received ranitidine 100 mg intravenously every 12 h. The two groups were matched for sex, age, location of bleeders, endoscopic findings, shock, and initial hemoglobin. Results: Hemostasis was obtained in 35 (83.3{\%}) of the octreotide group, and 23 (54.8{\%}) of the control group (p <0.01). Volume of blood transfused, numbers of patients receiving aggressive management (endoscopic hemostasis or operation), and hospital stay were significantly less in the octreotide group as compared with those of the controls (p <0.05, p <0.05 and p <0.001, respectively). No obvious side effect was found in the octreotide group. Conclusion: We suggest that octreotide is a safe and effective drug in arresting peptic ulcer hemorrhage. It may be used as the first-line therapy for a patient with massive peptic ulcer hemorrhage before he is transferred to a medical center.",
keywords = "Hemostasis, Operation, Rebleeding, Shock",
author = "Lin, {H. J.} and Perng, {C. L.} and K. Wang and Lee, {C. H.} and Lee, {S. D.}",
year = "1995",
language = "English",
volume = "42",
pages = "856--860",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "6",

}

TY - JOUR

T1 - Octreotide for arrest of peptic ulcer hemorrhage - A prospective, randomized controlled trial

AU - Lin, H. J.

AU - Perng, C. L.

AU - Wang, K.

AU - Lee, C. H.

AU - Lee, S. D.

PY - 1995

Y1 - 1995

N2 - Background/Aims: A prospective, randomized controlled trial was performed over a 10-month period to evaluate the hemostatic effects of octreotide and ranitidine in 84 patients with active peptic ulcer bleeding or nonbleeding visible vessels at the ulcer bases. Patients and Methods: Forty-two patients received octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 ± 0.6 days (mean ± SD). The other 42 patients received ranitidine 100 mg intravenously every 12 h. The two groups were matched for sex, age, location of bleeders, endoscopic findings, shock, and initial hemoglobin. Results: Hemostasis was obtained in 35 (83.3%) of the octreotide group, and 23 (54.8%) of the control group (p <0.01). Volume of blood transfused, numbers of patients receiving aggressive management (endoscopic hemostasis or operation), and hospital stay were significantly less in the octreotide group as compared with those of the controls (p <0.05, p <0.05 and p <0.001, respectively). No obvious side effect was found in the octreotide group. Conclusion: We suggest that octreotide is a safe and effective drug in arresting peptic ulcer hemorrhage. It may be used as the first-line therapy for a patient with massive peptic ulcer hemorrhage before he is transferred to a medical center.

AB - Background/Aims: A prospective, randomized controlled trial was performed over a 10-month period to evaluate the hemostatic effects of octreotide and ranitidine in 84 patients with active peptic ulcer bleeding or nonbleeding visible vessels at the ulcer bases. Patients and Methods: Forty-two patients received octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 ± 0.6 days (mean ± SD). The other 42 patients received ranitidine 100 mg intravenously every 12 h. The two groups were matched for sex, age, location of bleeders, endoscopic findings, shock, and initial hemoglobin. Results: Hemostasis was obtained in 35 (83.3%) of the octreotide group, and 23 (54.8%) of the control group (p <0.01). Volume of blood transfused, numbers of patients receiving aggressive management (endoscopic hemostasis or operation), and hospital stay were significantly less in the octreotide group as compared with those of the controls (p <0.05, p <0.05 and p <0.001, respectively). No obvious side effect was found in the octreotide group. Conclusion: We suggest that octreotide is a safe and effective drug in arresting peptic ulcer hemorrhage. It may be used as the first-line therapy for a patient with massive peptic ulcer hemorrhage before he is transferred to a medical center.

KW - Hemostasis

KW - Operation

KW - Rebleeding

KW - Shock

UR - http://www.scopus.com/inward/record.url?scp=0029592090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029592090&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 856

EP - 860

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 6

ER -